News
Oral edaravone is filed in Japan to treat Amyotropic Lateral Sclerosis.- Mitsubishi Tanabe
Mitsubishi Tanabe Pharma has filed a new drug application in Japan for an oral suspension version of its ALS treatment edaravone, which is currently available in an IV infusion form under the brand name of Radicut.
Oral edaravone, also known as MT-1186, was developed to reduce the burden of treatment on ALS patients, such as injection pain and outpatient visits. In Japan, the company aims to get the new version approved and launched in the year through March 2023.
Condition: Amyotrophic Lateral Sclerosis/Lou Gehrig's Diseas
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.